Prof Andrew Owen BSc MSc PhD FSB

Professor Molecular and Clinical Pharmacology

    About

    Personal Statement

    Andrew Owen, Ph.D. FSB is a Professor in the Department of Molecular and Clinical Pharmacology. He is also affiliated to the MRC Centre for Drug Safety Science and the Wolfson Centre for Personalised Medicine. Professor Owen has contributed to over 110 original research and review publications, book chapters and patent applications. In recent years, research funding has been secured from the Medical Research Council, Engineering and Physical Sciences Research Council, US National Institutes of Health and the British Society for Antimicrobial Chemotherapy. He is Chair of the British Society for Nanomedicine. (www.BritishSocietyNanomedicine.org), a fellow of the Society of Biology and a member of the Nanomed Focus Group Steering Committee, British Pharmacological Society and Critical Path to TB Drug Regimens. Professor Owen is also a member of the editorial board for Nanomedicine: nanotechnology, biology and medicine.

    Prizes or Honours

    • 2007 SAGE LECTURER OF THE YEAR (WORLD LEADERSHIP FORUM, 2007)
    • Presentation ranked in the top 5 for the Pharmacology section (13th conference on retroviruses and opportunistic infections, 2006)
    • Presentation ranked in the top 5 for the Pharmacology section (12th conference on retroviruses and opportunistic infections, 2005)
    • Presentation ranked in the top 5 for the Pharmacology section (11th conference on retroviruses and opportunistic infections, 2004)
    • Presentation ranked in the top 5 for the Pharmacology section (10th conference on retroviruses and opportunistic infections, 2003)
    • Winner of the Best Oral Communication in the Clinical Section (British Pharmacological Society, 2000)

    Other Personal Distinctions

    • Opportunities and challenges in development of solid drug nanoparticles for HIV treatment (Centre de Recherche Public de la Santé, 2014)
    • Nanomedicine: What the clinician should know (University of Turin, 2014)
    • Nanotechnology-enabled therapies for improved delivery of antiretroviral drugs (University of Cambridge, 2014)
    • The application of nanotechnology to improve bioavailability of antiretroviral drugs (Modular Training Programme in Applied Toxicology, Nanotoxicology, University of Surrey, Guilford, UK, 2011)